Novacta Therapeutics and O2h (Oxygen Healthcare) Announce A Multi FTE Medicinal Chemistry Collaboration
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
“Following two very successful projects, we are excited to enter a third collaboration that combines the strengths of both companies.” said Dr. Sjoerd Wadman, Head of Chemistry at Novacta Therapeutics.
A view of the newly constructed lab at the 10,000 sq.m, Shirish Research Campus at Ahmedabad, India.
Sunil Shah, CEO of O2h said “We are excited to be a part of and support the research programs that Novacta is pioneering in the area of Lantibiotics and Bacteriocins. The large investment that they have received to date is testament to the scientific breakthroughs that they have made in this area”.
Novacta Therapeutics is the newly formed division of Novacta, focused exclusively on the discovery and development of novel antibacterial and antiviral agents to treat severe and difficult bacterial and viral infections. Following the appointment of a new managerial team, Novacta Therapeutics was formed in 2008 as a result of a strategic decision to focus exclusively on the company's product pipeline. Novacta developed its product pipeline based on exploiting the potent pharmacological properties of lantibiotics - a drug class that, although exhibiting superior anti-infective properties, until now has been underexploited due to the lack of adequate research tools - and bacteriocins-proteinaceous toxins produced by bacteria to inhibit the growth of similar or closely related bacterial strain(s).
A view of the newly constructed lab at the 10,000 sq.m, Shirish Research Campus at Ahmedabad, India.
Sunil Shah, CEO of O2h said “We are excited to be a part of and support the research programs that Novacta is pioneering in the area of Lantibiotics and Bacteriocins. The large investment that they have received to date is testament to the scientific breakthroughs that they have made in this area”.
Novacta Therapeutics is the newly formed division of Novacta, focused exclusively on the discovery and development of novel antibacterial and antiviral agents to treat severe and difficult bacterial and viral infections. Following the appointment of a new managerial team, Novacta Therapeutics was formed in 2008 as a result of a strategic decision to focus exclusively on the company's product pipeline. Novacta developed its product pipeline based on exploiting the potent pharmacological properties of lantibiotics - a drug class that, although exhibiting superior anti-infective properties, until now has been underexploited due to the lack of adequate research tools - and bacteriocins-proteinaceous toxins produced by bacteria to inhibit the growth of similar or closely related bacterial strain(s).
